NEWS
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, a leader in antiviral nanomedicines, presents the progress of its drug candidate NV-387, which has completed Phase I clinical trials with no adverse events reported. NV-387 has demonstrated significant efficacy against various viruses, including RSV, Influenza, and coronavirus, in preclinical studies.
The company plans to advance NV-387 to Phase II trials, targeting pediatric RSV treatment.
NanoViricides estimates a potential market size of $16 billion in three years for diseases NV-387 aims to treat.
Additionally, the company is developing NV-HHV-1 for herpesvirus-related conditions and possesses a cGMP-compliant manufacturing facility, supporting its clinical and market entry plans.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1270Followers
76Following
8941Visitors
Follow